Abvc biopharma enters into $3.0 million clinical services contract with neucen biomed

Fremont, ca, may 03, 2022 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that biokey, a wholly-owned subsidiary of the company based in fremont, california, has entered into a $3.0 million clinical services contract with neucen biomed co. ltd. to guide two neucen drug products, cen501 and neu001, through completion of phase ii clinical studies under u.s. fda ind regulatory requirements.
ABVC Ratings Summary
ABVC Quant Ranking